Febrile seizure risk following monovalent COVID-19 mRNA vaccination in US children aged 2–5 years

Steven A. Anderson; Elizabeth R. Smith; Zhiruo Wan; Kandace L. Amend; Alex Secora; Djeneba Audrey Djibo; Kamran Kazemi; Jennifer Song; Lauren Parlett; John D. Seeger; Nandini Selvam; Cheryl N. McMahill-Walraven; Mao Hu; Yoganand Chillarige; Richard A. Forshee

doi:10.1016/j.vaccine.2026.128225

February 4, 2026VaccineOpen Access

Febrile seizure risk following monovalent COVID-19 mRNA vaccination in US children aged 2–5 years

View Full Paper

Ask AI

Bookmark

Share

Key Points

To assess the risk of febrile seizures following mRNA COVID-19 vaccination in young children.
Analyzed vaccination data for children aged 2-5 years
Calculated incidence rate ratios for febrile seizures
Focused on the period 0-1 days post-vaccination
Identified a small elevated incidence rate ratio of febrile seizures
Found this increase to be within a short timeframe post-vaccination

Implication

Analysis shows elevated febrile seizure rates in children following COVID-19 mRNA vaccination, suggesting careful monitoring is needed.

Abstract

Among children aged 2-5 years, the analysis showed a small elevated incidence rate ratio of febrile seizures in the 0-1 days following the mRNA-1273 vaccination.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Anderson et al. (2026) studied this question.

synapsesocial.com/papers/698827570fc35cd7a8845faa https://doi.org/10.1016/j.vaccine.2026.128225

View Full Paper

Ask AI

Bookmark

Share

Febrile seizure risk following monovalent COVID-19 mRNA vaccination in US children aged 2–5 years

Key Points

Implication

Abstract

Discussion

Cite This Study

Febrile seizure risk following monovalent COVID-19 mRNA vaccination in US children aged 2–5 years

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading